Antitumor effect of B16 melanoma cells genetically modified with the angiogenesis inhibitor rnasin.
The growth of new blood vessels is an essential condition for the development of tumors with a diameter greater than 1-2 mm and also for their metastatic dissemination. RNasin, the placental ribonuclease inhibitor, is known to have antiangiogenic activity through the inhibition of angiogenin and basic fibroblast growth factor. Nevertheless, the administration of the recombinant form of a protein poses several limitations; as a result, we have studied the antitumor effect of RNasin in a murine gene therapy model. RNasin cDNA was subcloned into the pcDNA3 expression vector, and the resulting recombinant plasmid was used to transfect the B16 murine melanoma cell line. An RNasin inverted construction was used as control. Mice intravenously injected with clones expressing RNasin showed a significant inhibition of tumor metastatic progression with respect to control groups (P<.001) and survived longer (P<.001). Tissue sections from RNasin-expressing cell tumors showed a lower number of blood vessels when compared to tissue sections from mice lungs that had been inoculated with control cell lines. The results of these experiments show that the genetic modification of tumor cells with RNasin cDNA yields a significant antitumor effect, and suggest that this effect is at least partially the result of angiogenesis inhibition.
Botella-Estrada
R
R
Servicio de Dermatología, Instituto Valenciano de Oncologia, Universitat de València, Spain. rbot@vlc.servicom.es
Malet
G
G
Revert
F
F
Dasí
F
F
Crespo
A
A
Sanmartín
O
O
Guillén
C
C
Aliño
S F
SF
D020533:Angiogenesis Inhibitors / Q000235:genetics*; D000818:Animals; D002455:Cell Division; D017931:DNA Primers / Q000737:chemistry; D004791:Enzyme Inhibitors; D015870:Gene Expression; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors; D006801:Humans; D007124:Immunoenzyme Techniques; D008175:Lung Neoplasms / Q000098:blood supply / Q000235:genetics / Q000628:therapy*; D008546:Melanoma, Experimental / Q000098:blood supply / Q000235:genetics / Q000628:therapy*; D051379:Mice; D009389:Neovascularization, Pathologic / Q000628:therapy*; D010926:Placental Hormones / Q000235:genetics*; D012333:RNA, Messenger / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012260:Ribonucleases / Q000037:antagonists & inhibitors; D014158:Transcription, Genetic; D014162:Transfection; D014407:Tumor Cells, Cultured
D020533:Angiogenesis Inhibitors; D017931:DNA Primers; D004791:Enzyme Inhibitors; D010926:Placental Hormones; D012333:RNA, Messenger; C022052:placental ribonuclease inhibitor; D012260:Ribonucleases